Vardenafil: A selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 7, 2007, Pages 965-974

  Reffelmann, Thorsten ^a,b   Kloner, Robert A ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Atherogenic risk factors; Cardiovascular disease; Erectile dysfunction; Nitrates; Phosphodiesterase 5; Vardenafil

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CYCLIC GMP; CYTOCHROME P450 3A4; ERYTHROMYCIN; GLYCERYL TRINITRATE; INDINAVIR; KETOCONAZOLE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; RITONAVIR; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL; VASODILATOR AGENT; CYCLIC GMP PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SULFONE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BACKACHE; BLEEDING TIME; BLURRED VISION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLOR VISION DEFECT; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; FLUSHING; FOOD DRUG INTERACTION; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; IC 50; LIPID DIET; NAUSEA; NONHUMAN; OPTIC NERVE DISEASE; PRIAPISM; QT PROLONGATION; RHINITIS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SYNCOPE; URTICARIA; ANIMAL; DRUG ANTAGONISM; IMPOTENCE; MALE; REVIEW;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PIPERAZINES; SULFONES; TRIAZINES; VASODILATOR AGENTS;

EID: 34249751036     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.7.965     Document Type: Article

References (69)

1. LAUMANN EO, WEST S, GLASSER D, CARSON C, ROSEN R, KANG JH: Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: From the male attitudes regarding sexual health survey. J. Sex. Med. (2006) in press.
2. BRAUN M, WASSMER G, KLOTZ T, REIFENRATH B, MATHERS M, ENGELMANN U: Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int. J. Impot. Res. (2000) 12:305-311.
3. JOHANNES CB, ARAUJO AB, FELDMAN HA, DERBY CA, KLEINMAN KP, MCKINLAY JB: Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J. Urol. (2000) 163:460-463.
4. BILLUPS KL: Endothelial dysfunction as a common link between erectile dysfunction and cardiovascular disease. Current Sexual Health Reports (2004) 1:137-141.
5. REFFELMANN T, KLONER RA: Sexual function in hypertensive patients receiving treatment. Vasc. Health Risk Manag. (2006) 2:447-455.
6. LEVINE LA: Diagnosis and treatment of erectile dysfunction. Am. J. Med. (2000) 109:3S-12S.
7. REFFELMANN T, KLONER RA: Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr. Pharm. Des. (2006) 12:3437-3494.
8. GOLDSTEIN I, LUE TF, PADMA-NATHAN H et al.: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. (1998) 338:1397-1404.
9. BROCK GB, MCMAHON CG, CHEN KK et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J. Urol. (2002) 168:1332-1336.
10. NAGAO K, ISHII N, KAMIDONO S, OSADA T: Safety and efficacy of vardenafil in patients with erectile dysfunction: results of a bridging study in Japan. Int. J. Urol. (2004) 11:515-524.
11. MONTORSI F: Tolerability and safety of apomorphine SL (Ixense). Int. J. Impot. Res. (2003) 15:S7-S9.
12. FAGAN TC, BUTTLER S, MARBURY T, TAYLOR A, EMONDS A: Cardiovascular safety of sublingual apomorphine in patients on stable dose of oral antihypertensive agents and nitrates. Am. J. Cardiol. (2001) 88:760-766.
13. DOGGRELL SA: Clinical potential of nitric oxide-independent soluble guanylare cydase activators. Curr. Opin. Investig. Drugs. (2005) 6:874-878.
14. WALLIS RM, CORBIN JD, FRANCIS SH, ELLIS P: Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. (1999) 83:3C-12C.
15. GRESSER U, GLEITER CH: Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitor sildenafil, vardenafil and tadalafil: review of the literature. Eur. J. Med. Res. (2002) 7:435-446.
16. FRANCIS SH, TURKO IV, CORBIN: Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Bio. (2001) 65:1-52.
17. BERKELS R, KLOTZ T, STICHT G, ENGLEMANN U, KLAUS W: Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor Sildenafil. J. Cardiovasc. Pharmacol. (2001) 37:413-421.
18. BORTOLOTTI M, MARI C, LOPILATO C, PORAZZO G, MIGLIOLI G: Effects of sildenafil on esophageal motility of patients with achalasia. Gastroenterology (2000) 118:253-257.
19. CHEITLIN MD; HUTTER AM, BRINDIS RG et al.: ACC/AHA Expert Consensus Document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J. Am Coll. Cardiol. (1999) 33:273-282.
20. SENZAKI H, SMITH CJ, JUANG GJ et al.: Cardiac phosphodiesterase 5(cGMP-specific) modulates β-adrenergic signaling in vivo and is downregulated in heart failure. FASEB J. (2001) 15:1718-1726.
21. STIEF CG, ÜCHERT S, BECKER AJ et al.: Effects of Sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology (2000) 55:146-150.
22. SUGIYAMA A, SATOH Y, SHIINA H, TAKAHARA A, YONEVAMA M, HASHIMOTO K: Cardiac electrophysiologic and hemodynamic effects of Sildenafil, a PDE5 inhibitor, in anesthetized dogs. J. Cardiovasc. Pharmacol. (2001) 38:940-946.
23. DAS S, MAULIK N, DAS DK. KADOWITZ PJ, BIVALACQUA TJ: Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′-monophosphate specific phosphodiesterase 5. Drugs Exp. Clin. Res. (2002) 28:213-219.
24. OCKAILI R, SALLOUM F, HAWKINS J, KUKREJA RC: Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am. J. Physiol. (2002) 283:H263-H269.
25. FEENSTRA J, VAN DRIE-PIERIK RJ, LACLE CF, STRICKER BH: Acute myocardial infarction associated with sildenafil. Lancet (1998) 352:957-958.
26. REFFELMANN T, KLONER RA: Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation (2003) 108:239-244.
27. SWISSA M, OHARA T, LEE MH et al.: Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmia in the swine right ventricle. Am. J. Physiol. (2002) 282:H1787-H1792.
28. GEELEN P, DROLET B, RAIL J et al.: Sildenafil citrate (Viagra) prolongs cardiac repolarisation by blocking the rapid component of the delayed rectifier potassium current. Circulation (2000) 102:275-277.
29. SAENZ DE TEJADA, ANGULO J, CUEVAS P et al.: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. (2001) 13:282-290.
30. BISCHOFF E: Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot. Res. (2004) 16:S11-S14.
31. SUPURAN CT, MASTROLORENZO A, BARBARO G, SCOZZAFAVA A: Phosphodiesterase 5 inhibitors - drug design and differentiation based on selectivity pharmacokinetic and efficacy profiles. Curr. Pharm. Des. (2006) 12:3459-3465.
32. SUSSMAN DO: Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J. Am. Osteopath. Assoc. (2004) 104:511-515.
33. BAYER PHARMACEUTICAlS CORP.: Levitra® (vardenafil HCl) prescribing information. Bayer Pharmaceuticals Corp., West Haven (CT) USA (2005).
34. SACHSE R, ROHDE G: Safety tolerability and pharmacokinetics of multiple dose treatment with the new PDE5-inhibitor BAY 38-9456. Eur. Urol. (2000) 37(Suppl. 2):81
35. RHODE G, WENSING G, UNGER S et al.: The pharmacokinetics of vardenafil, a new selective PDE 5 inhibitor, is minimally affected by coadministration with cimetidine and ranitidine. Pharmacotherapy (2001) 21:10.
36. KLONER RA: Cardiovascular effects of the 3 phosphodieserase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation (2004) 110:3149-3155.
37. JACKSON G, ROSEN RC, KLONER RA, KOS JB: The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J. Sex. Med. (2006) 3:28-36.
38. BAYER PHARMACEUTICALS CORP.: Levitra® (vardenafil HCl) prescribing information. Bayer Pharmaceuticals Corp., West Haven (CT) USA (2003).
39. BISCHOFF E, NIEWOEHNER U, HANING H, et al.: The oral efficacy of Vardenafil for inducing penile erection in a conscious rabbit model. J. Urol. (2001) 165:1316-1316.
40. PORST H, ROSEN R, PADMA-NATHAN H et al.: The efficacy and tolerability of vardenafil, a new oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int. J. Impot. Res. (2001) 13:192-199.
41. GOLDSTEIN I, YOUNG JM, FISCHER J, BANGERTER K, SEGERSON T, TAYLOR T: Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care (2003) 26:777-783.
42. ISHII H, NAGAO K, FUJIKAWA K, TACHIBANA I, IWAMOTO Y, KAMIDONO S: Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int. J. Urol. (2006) 13:1066-1072.
43. GIULIANO P, RUBIO-AURIOLES E, KENNELLY M et al.: Efficacy and safety of vardenafil in men with erectile dyfunction caused by spinal cord injury. Neurology (2006) 66:210-216.
44. GIULIANO F, DONATUCCI C, MONTORSI F et al.: Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int. (2005) 95:110-116.
45. DONATUCCI C, EARDLEY I, BUVAT J et al.: Vardenafil improves sexual function in men with erectile dysfunction irrespective of disease severity and disease classification. J. Sex. Med. (2004) 1:301-309.
46. DONATUCCI C, TAYLOR T, THIBONIER M, BANGERTER K, GITTELMAN M, CASEY R: Vardenafil improves patient satisfaction with erection hardness, orgasmic function, and overall sexual experience, while improving quality of life in men with erectile dysfunction. J. Sex. Med. (2004) 1:185-192.
47. EDWARDS D, HACETT G, COLLINS O, CURRAM J: Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naïve men with ED and their partner. J. Sex. Med. (2006) 3:1028-1036.
48. HATZICHRISTOU D, CUZIN B, MARTIN-MORALES A et al.: Vardenafil improves satisfaction rates, depressive symptomatology, an self confidence in a broad population of men with erectile dysfunction. J. Sex. Med. (2005) 2:109-116.
49. HELLSTROM WJ, GITTELMAN M, KARLIN G et al.: Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology (2003)61:8-14.
50. STIEF C, PORST H, SAENZDE TEJADA I, ULBRICH E, BENEKE M: Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int. J. Clin. Pract. (2004) 58:230-239.
51. HALLEN K, WIKLUND NP, GUSTAFSSON LE: Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitricoxide from the rabbit corpus cavernosum. Br. J. Pharmacol. (2007) 150:353-360.
52. VALIQUETTE L, MONTORSI F, AUERBACH S, VARDENAFIL STUDY GROUP: First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I. Int. J. Clin. Pract. (2006) 60:1378-1385.
53. ZIEGLER D, MERFORT F, VAN AHLEN H, YASSIN A, REBLIN T, NEUREITHER M: Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J. Sex. Med. (2006) 3:883-891.
54. RUBIO-AURIOLES E, PORST H, EARDLEY I et al.: Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J. Sex. Med. (2006) 3:1037-1049.
55. HATZICHRISTOU DG, ALIOTTA P, AUERBACH S et al.: Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis. Clin. Ther. (2005) 27:1452-1461.
56. KLONER BA, MOHAN P, SEGERSON T et al.: Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of five placebo controlled trials. J. Am. Coll. Cardiol. (2003) 41(Suppl A): 276A-277A.
57. PADMA-NATHAN H, PORST H, EARDLEY I et al.: Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Presented at The American Society Of Hypertension, 17th Annual Scientific Meeting. New York, NY (16-20 May 2002).
58. ROHDE G, JORDAN P: Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy. Pharmacotherapy (2002) 22:4 18 (Abstr.).
59. VAN AHLEN H, WAHLE K, KUPPERW, YASSIN A, REBLIN T, NEUREITHER M: Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensiveness. J. Sex. Med. (2005) 2:856-864.
60. KLONER RA: Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am. J. Cardiol. (2005) 96:42M-46M.
61. WYSOWSKI DK, FARINAS E, SWARTZ L: Comparison of reported and expected deaths in sildenafil (Viagra) users. Am. J. Cardiol. (2002) 89:1331-1334.
62. THADANI U, SMITH W, NASH S et al.: The effect of vardenafil, a potent and highly selective phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll. Cardiol. (2002) 40:2006-2012.
63. MORGANROTH J, ILSON BE, SHADDINER BC et al.: Evaluation of vardenafil and sildenafil on cardiac repolarization. Am. J. Cardiol. (2004) 93:1378-1383.
64. BELLA AJ, BRANT WO, LUE TF, BROCK GB: Non-arteritic anterior optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. Can. J. Urol. (2006) 13:3233-3238.
65. MCGEE HT, EGAN RA, CLARK WM: Visual field defects and intracerebral hemorrhage associated with use of vardenafil (Levitra). Neurology (2005) 64: 1095-1096.
66. STRIANO P, ZARA F, MINETTI C, STRIANO S: Epileptic seizures can follow high doses of oral vardenafil. BMJ (2006) 333:785.
67. KOUSSA S, HAGE CHAHINE S, TOHME A, RIACHI M: Epileptic seizures and vardenafil. Rev. Neurol. (2006) 162:651-652.
68. MINCIULLO PL, SAIJA A, PATAFI M et al.: Vardenafil-induced generalized urticaria. J. Clin. Pharm. Ther. (2004) 29:483-484.
69. GHOFRANI HA, VOSWINCKEL R, REICHENBERGER F et al.: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. (2004) 44:1488-1496.